Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Sheeba Irshad, Irene del Molino del Barrio et al.|The Lancet Oncology|2021Cited by 614
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesLeticia Monin, Sheeba Irshad, Adam G. Laing et al.|medRxiv|2021Cited by 61